Investigating the effect of EstroG-100 herbal extract on the improvement of hot flashes in postmenopausal women in two intervention and control groups.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220716055479N1

Enrollment

Registered

2022-10-17

Start date

2021-12-27

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hot flash.

Interventions

Intervention 1: Intervention group: recipient of ESTROG-100, which this plant extract contains a combination of three plant roots (Cynanchum wilfordii Hemsley plants (Catus family), Phlomis umbrosa Tu

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Willingness to participate in the study Normal BMI Absence of underlying disease

Exclusion criteria

Exclusion criteria: Unwillingness to participate in the study Use of hormonal drugs containing estrogen and progesterone in the last three months drug use BMI greater than 40 irregular bleeding within 1 year after menopause hysterectomy uncontrolled blood pressure thyroid diseases diabetes mellitus history of hormone related cancers

Design outcomes

Primary

Measure	Time frame
Investigating the hot flush symptoms based on the patients' answers (the criteria of a questionnaire designed with three states of mild, moderate and severe). Timepoint: 12weeks. Method of measurement: In the first visit, for those eligible to enter the study, they were asked to fill out the form related to severity (mild: sudden hot flush, moderate: sudden hot flush with severe sweating, severe: sudden hot flush with Sweating and interference with daily activities), the number of hot flashes (within a week), should be completed weekly from one week before the treatment to 12 weeks after the treatment and delivered at each visit.In case of not being able to visit these people in person, information will be collected on a weekly basis and during phone calls. Medicines were delivered to people in the clinic during three stages at the beginning of the treatment, the end of the 4th week and the end of the 8th week.	—

Measure

Time frame

Investigating the hot flush symptoms based on the patients' answers (the criteria of a questionnaire designed with three states of mild, moderate and severe). Timepoint: 12weeks. Method of measurement: In the first visit, for those eligible to enter the study, they were asked to fill out the form related to severity (mild: sudden hot flush, moderate: sudden hot flush with severe sweating, severe: sudden hot flush with Sweating and interference with daily activities), the number of hot flashes (within a week), should be completed weekly from one week before the treatment to 12 weeks after the treatment and delivered at each visit.In case of not being able to visit these people in person, information will be collected on a weekly basis and during phone calls. Medicines were delivered to people in the clinic during three stages at the beginning of the treatment, the end of the 4th week and the end of the 8th week.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGolnaz Fallah

Shahid Beheshti University of Medical Sciences

golnaz.fallah.talouki@gmail.com+98 21 7343 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026